Odyssey Therapeutics, Inc. Ttl Fee Amt
Odyssey Therapeutics, Inc. (ODTX) had Ttl Fee Amt of $19.63 thousand as of 2026-05-08, per its S-8 filed 2026-05-11.
Financial Statements › Notes
ffd:TtlFeeAmt · last filed 2026-05-11
- 2026-05-08: Ttl Fee Amt $19.63K.
- 2026-05-07: Ttl Fee Amt $6.46K.
- 2026-04-30: Ttl Fee Amt $37.85K.
- 2026-04-15: Ttl Fee Amt $13.81K.
| Period end | Ttl Fee Amt |
|---|---|
| 2026-05-08 | $19.63K S-8 · filed 2026-05-11 |
| 2026-05-07 | $6.46K S-1MEF · filed 2026-05-07 |
| 2026-04-30 | $37.85K S-1/A · filed 2026-05-04 |
| 2026-04-15 | $13.81K S-1 · filed 2026-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |